Promedior, Inc. is a clinical-stage biotechnology company developing novel therapeutics for the treatment of fibrotic diseases. Their lead product candidate, PRM-151, is being evaluated in multiple clinical trials for the potential treatment of fibrosis-related disorders such as idiopathic pulmonary fibrosis and myelofibrosis. Promedior's innovative approach targets the underlying cause of fibrosis, offering promise for patients in need of new treatment options.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 15 2026

9 Patents

#68 in Lexington, MA

#1,919 in Massachusetts

#32,503 in US

Lexington, MA, United States of America

Promedior, Inc.

Forward Citations = 30

11 inventors:

W Scott Willett (3 out of 3 patents)

Lynne Anne Murray (2 out of 2 patents)

Mark L Lupher, Jr (2 out of 2 patents)

4. Michael Scott Kramer (2 out of 2 patents)

5. David Paul Hesson (2 out of 7 patents)

Please report any incorrect information to [email protected]

2 patents (CIPO):

Please report any incorrect information to [email protected]

10 patents (EPO):

Please report any incorrect information to [email protected]